Trevi Therapeutics Inc at Needham Healthcare Conference Transcript
Hi, good morning. Welcome to Needham's 21st annual healthcare conference. I'm Serge Belanger, one of the healthcare analysts at Needham. Happy to have the Trevi Therapeutics team with us for our next session here. They are a clinical-stage biopharma focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Company reported exciting proof-of-concept results in the first quarter that I'm sure we're going to talk about in the next 40 minutes here.
So we have Jennifer Good, the company's CEO as well as Bill Forbes, the Chief Development Officer of the company. So I'll hand it over to you, Jennifer, so you can give us an overview of the company. And then we'll do some Q&A afterwards.
Great. Serge, thank you, and thank you to Needham for including us in your conference. We appreciate it. Bill and I are going to just take 15 minutes or so and run you through Trevi in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
